Search research articles
Contact Us
Filters
Showing results (151-160 of 202) with videos related to
Page
of 21
Sort By:
Evolutionary Applications
|
July 29, 2016
Hybridization and extinction
Marco Todesco, Mariana A Pascual, Gregory L Owens, et al.
ACS Medicinal Chemistry Letters
|
August 18, 2022
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors
David Harrison, Mark G Bock, John R Doedens, et al.
Journal of Medicinal Chemistry
|
December 10, 1993
Nanomolar-affinity, non-peptide oxytocin receptor antagonists
B E Evans, G F Lundell, K F Gilbert, et al.
Journal of Medicinal Chemistry
|
January 1, 1990
Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom
M G Bock, R M DiPardo, B E Evans, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 1, 1991
In vitro pharmacological profile of a novel structural class of oxytocin antagonists
D J Pettibone, B V Clineschmidt, E V Lis, et al.
Journal of Medicinal Chemistry
|
December 24, 1993
Development of 1,4-benzodiazepine cholecystokinin type B antagonists
M G Bock, R M DiPardo, B E Evans, et al.
Journal of Medicinal Chemistry
|
December 1, 1988
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists
B E Evans, K E Rittle, M G Bock, et al.
European Journal of Pharmacology
|
April 24, 1991
Bradykinin agonist activity of a novel, potent oxytocin antagonist
D J Pettibone, B V Clineschmidt, E V Lis, et al.
Journal of Medicinal Chemistry
|
July 1, 1990
Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications
R M Freidinger, P D Williams, R D Tung, et al.
Journal of Medicinal Chemistry
|
October 1, 1986
Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility
M G Bock, R M DiPardo, K E Rittle, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 202) with videos related to
Sort By:
Page
of 21
Evolutionary Applications
|
July 29, 2016
Hybridization and extinction
Marco Todesco, Mariana A Pascual, Gregory L Owens, et al.
ACS Medicinal Chemistry Letters
|
August 18, 2022
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors
David Harrison, Mark G Bock, John R Doedens, et al.
Journal of Medicinal Chemistry
|
December 10, 1993
Nanomolar-affinity, non-peptide oxytocin receptor antagonists
B E Evans, G F Lundell, K F Gilbert, et al.
Journal of Medicinal Chemistry
|
January 1, 1990
Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom
M G Bock, R M DiPardo, B E Evans, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 1, 1991
In vitro pharmacological profile of a novel structural class of oxytocin antagonists
D J Pettibone, B V Clineschmidt, E V Lis, et al.
Journal of Medicinal Chemistry
|
December 24, 1993
Development of 1,4-benzodiazepine cholecystokinin type B antagonists
M G Bock, R M DiPardo, B E Evans, et al.
Journal of Medicinal Chemistry
|
December 1, 1988
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists
B E Evans, K E Rittle, M G Bock, et al.
European Journal of Pharmacology
|
April 24, 1991
Bradykinin agonist activity of a novel, potent oxytocin antagonist
D J Pettibone, B V Clineschmidt, E V Lis, et al.
Journal of Medicinal Chemistry
|
July 1, 1990
Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications
R M Freidinger, P D Williams, R D Tung, et al.
Journal of Medicinal Chemistry
|
October 1, 1986
Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility
M G Bock, R M DiPardo, K E Rittle, et al.
Page
of 21